SR One Capital Management, LP: 13F holdings
CIK 19102642026Q2
| Positions | 15 |
|---|
| Reported value | $1.0bn |
|---|
| Filed | 2026-08-12 |
|---|
Change since last quarter
| Positions | 15 (+1 vs prior quarter) |
|---|
| Reported value | $1.0bn (+13.5%) |
|---|
Top 10 holdings
| Security | Shares | Value | Weight |
|---|
| MANE Veradermics, Inc. | 2,401,868 | $295.3m | 28.4% |
| ZBIO Zenas BioPharma, Inc | 5,037,854 | $127.9m | 12.3% |
| CRISPR Therapeutics AG | 2,038,763 | $111.2m | 10.7% |
| Avalyn Pharma, Inc | 3,308,649 | $108.9m | 10.5% |
| DSGN Design Therapeutics, Inc. | 6,526,476 | $94.4m | 9.1% |
| Odyssey Therapeutics, Inc. | 3,794,883 | $71.0m | 6.8% |
| ALMS Alumis Inc. | 1,959,896 | $55.2m | 5.3% |
| ORIC ORIC Pharmaceuticals, Inc. | 4,615,384 | $50.0m | 4.8% |
| MLYS Mineralys Therapeutics Inc. | 1,563,966 | $42.2m | 4.1% |
| SPRY ARS Pharmaceuticals, Inc. | 4,012,903 | $32.1m | 3.1% |
Get the full book
import finzdata as yf
yf.Client().manager_holdings(cik="1910264")
Every position, quarter by quarter since 2013, with adds, trims and exits, on the look-back bundles.
Get a free API keySee history bundlesDownload free samples